Incyte targets $3–4B by 2030 and $8–10B peak sales
Incyte management outlined a dual strategy of core business growth plus pipeline execution, targeting $3–4 billion by 2030 and $8–10 billion peak sales post-2029. Oncology, hematology and immunology assets are progressing.